• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Novel 16-phenoxy and 18-(o, m or p)-substituted phenoxy derivatives of(dl)-9-keto-11α,15α-dihydroxy-17,18.19,20-tetranorprosta-4,5,13-trans-trienoic acid, the pharmaceutically acceptable, non-toxic lower alkyl esters and salts thereof and processes for the production of such compounds. These compounds possess prostaglandin-like activities and thus are useful in the treatment of mammals where prostaglandins are indicated. They are particularly useful as inhibitors of gastric acid secretion; and as agents for the control of asthmatic attack, because of their bronchodilating activity.
    公开号:SU1031407A3
    申请号:SU792786000
    申请日:1979-07-09
    公开日:1983-07-23
    发明作者:Р.Ван Хорн Альберт；Гэрей Габриэль；А.Эдвардс Джон
    申请人:Синтекс (Ю.С.А) Корпорейшн (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to methods for the preparation of derivatives not described in literature (α-phenoxy-9-ketoprostatrienoic acid of general formula I: where R is hydrogen or C-alkyl, or their salts possessing pharmacological activity. A method is known for producing hydroxyl-containing compounds by acid hydrolysis of 0- trialkylsilyl derivatives of tn. Using the known reaction, it is possible to obtain new pharmacologically active derivatives (CoCl) -1b-phenoxy-9-ketoprostatrienoic acid of general formula I or their salts. The purpose of the invention is to obtain (otS) -1b-phenoxy-9-ketoprostatrienoic acid derivatives of the general formula 1 of their salts, which have valuable pharmacological properties. This goal is achieved by the proposed method of obtaining {d8b -1b-phenoxy-9-ketoprostatrienoic acid of the general formula G or their salts, which consists in combining some of the general formula O With CeHs (CHglSib OgilCHs) / 3 C (CH3). (3) 3 where R is C – C-alkyl, Subjected to acidic hydrolysis at 0–35 ° C and, if necessary, the resulting compound of the general formula 1, where R is C – C-alkyl, is subjected to hydrolysis in the presence of pancreatic lipase at room temperature. to obtain a compound of general formula I where P is hydrogen, or, if necessary, a compound of general formula 1 where ft is hydrogen, is treated diazoally to obtain compounds of general formula T, where P.-. Kil, or base at 0-iOQ ° C to obtain salts, which, if necessary, are treated with an acid to obtain a compound of general formula I, where R is hydrogen, after which the desired npoflyKiH are isolated using known methods. Compounds of general formula I are obtained by acid hydrolysis in the presence of organic or nonorganic acid, for example acetic acid, monochloroacetic acid, propionic acid, or mixtures thereof, preferably in the presence of acetic acid at a temperature of preferably 15 to 25 ° C for 10-24 hours , preferably 15-20 hours. Treatment of an acid of formula I, where R is hydrogen, with an excess of a diazoalkane, such as diazomethane, diazoethane or diazopropane, is carried out in diethyl ether or in a solution of methylene chloride. Salts of 9-ketop1 remienic acid are obtained by treating the corresponding free acids with approximately one molar equivalent pharmaceutically. an acceptable base, including inorganic and organic bases, per 1 molar equivalent of free acid. Salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, magnesium, ferrous, zinc, copper, manganese, aluminum, ferric, trivalent manganese salts. Ammonium, potassium, sodium, calcium and magnesium salts are particularly suitable. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as copi, isopropylamine, trimethylamine, diethylamine, triethylamine , tripropylamine, ethanolamine, 2-dimethylamine, lysine, arginine, histidine, caffeine, procaiya, hydrobamine, cloin, betaine, ethylene diamine, glucosamine, methyl glucosamine, theobroin, purines, piperazi and, piperidine, N -etilpiperidina, poliaminovyh resins, etc. Particularly, the other organic non-toxic bases are isopropylamine, diethylamine, piperidine, tromethamine, cloin and caffeine. The reaction is carried out in water, or in combination with an inert organic water-miscible solvent, preferably at room temperature. Typical inert, miscible with water, solvents are methanol, ethanol, isopropanol, butanol, acetone, dioxane or tetrahydrofuran. The molar ratio between the free acid and the M base used is chosen in such a way as to create the ratio desired for this particular salt. For example, to obtain the calcium or magnesium salts, the starting acid is treated with at least 0.5 molar equivalent of pharma-. a chemically acceptable base to form a neutral salt. When salts are obtained, at least one third of the molar equivalent of the pharmaceutically acceptable base is consumed for the preparation of the neutral salt. Calcium and magnesium salts of prostatrienoic acid can be prepared by treating the corresponding sodium or potassium salts with at least 0.5 molar equivalents. a ribbon of calcium chloride or magnesium chloride in an aqueous solution or in combination with HHepTHbihi, miscible with water, with a solvent at 20-100 ° C. Preferably, the prostateic acid gshuminium salts are obtained by treating the corresponding free acid with at least one; n third molar equivalent of an alkylate, such as aluminum triethylate, aluminum tripropylate in a hydrocarbon solvent such as benzene, xylene, cyclohexane, at 20 -80 ° C. Compounds of formula I possess biological activity similar to prostaglandins and are used to treat mammals in cases where the use of prostaglandins is indicated. These compounds are acceptable for the treatment of asthmatic attacks, as they have bronchoscopic properties. They also have antiallergic properties and inhibit the release of a mediator. In addition, they are useful in treating mammals from bronchial infections and in cases where the use of bronchodilators is indicated. The compounds also have vasodilatory ability and are useful for treating or temporarily alleviating hypertension in mammals, and they also have the activity of a central nervous system depressant in a mammal (they are useful as BeiatecTB family. Compounds of formula I are powerful inhibitor. gastric juice secretion and induction of ulcers and are extremely useful in treating and preventing the formation of gastric ulcers and duodenal ulcers. Example 1. To a solution of 0.5 g of methyl ester (dt-SelL, lloi, 15 -trioxy-1b-phenoxy-17,18,19,20-tet.transprost-4, 5,13gtrans-trivine KIS7YUTA and 0.45 g of imidazole in 19 mp anhydrous dimethylfrmamide with stirring at -25 ° C, add 0, 5 rt-butyldimethylsilyl chloride. The reaction solution is stirred at -30 for 16 h, 250 ml of ether are added and the ether solution is washed with two 50 ml portions of water. The ether solution is dried with anhydrous sodium sulfate and evaporated bt under reduced pressure. Get methyl ester (dP) -9ot-oxy-llot, l5ct-bic-tert. -Butyldimethylsiloxy-16-phenoxy-17, 18, 19,20-teryorprost-4, 5,13-tr, ans-trianoic acid and a small amount of tri- and mono-tert-butyldimethylsilyl derivatives. Crude, the reaction mixture was chromatographed on a column containing 100 g of silica gel, and eluted with ethyl acetate: hexane (15:85). (C5l6) -9cl-oKCH-llet., L5ot-6HC-tert-butyldimethylsilyloxy-16-phenoxy-17, 18,19,2 O-tetranorprost-4,5, 13-trans-tienoic acid is obtained. Mass, spectrum (m / e): 645 (C4H9). The more polar monosilylated and less polar trisilylated chromatographic fractions can be converted back to the starting materials: a solution of 0.2-1 g of mono- and trisilyl derivatives in 250 ml of a mixture of acetic acid and water Sb5 / 35 by volume) is transferred at kc "1g" the temperature for 15-20 hours, acetic acid and water are removed under reduced pressure, after which azeotropic vacuum distillation is carried out using 100 ml of toluene. Regenerated triol can be | can be converted into its 11, 15s1 (.- bi-c-tert-but-dimethyl alkyl iloxyl derivative in the manner described. Example 2, O, 77 g of anhydrous chromium trioxide is added to a 1.5-mb anhydrous pyridine solution 20 h < i > anhydrous dichloromethane and stirring in at capacity of dried nitrogen for 15 minutes, after which a solution of 305 mg of methyl (cSv) -9 oxy-1 loL, 15o6-bis-tert-butyldimethylsilyloxy-1b-phenoxy-17 is added , 18,19,20-tetranor-prosta-4/5, 13-trans-trienoic acid in 10 ml of anhydrous dichloromethane and p & mixture is stirred for 30 min at 2 0 C. The solution is decanted from the precipitate and the residue is washed with two 200 ml portions of ether. The organic solutions are combined, mixed twice with three 50 ml portions of water and dried with anhydrous sodium sulfate. After evaporation under reduced pressure, an oily residue is obtained chromatographed on a silica gel column using ethyl acetate: hexane {85:15) for elution. The methyl ester is obtained (: yo) -9-keto-11 "/., 15c # -bis-tert-butyl dicyutylsilyloxy-1b-phenoxy-17, 18,19, 20-tetrans") is simple-4,5,13- trans-trienoic acid. Example 3. A solution of 230 mg of methyl ester (dP-9-keto-11o, 151gbis-tert-butyldimethylsilyloxy-1b-phenoxy-17, 18,20-tetranoproprosta-4, 5, 13-trans-trienoic acid in
    权利要求:
    Claims (1)
    [1]
    The method of obtaining derivatives (<9c) -1b-phenoxy-9-ketoprostatrienoic acid of the General formula I:
    where R is hydrogen or C yC in alkyl, or their salts, characterized in that the compound of general formula lit
    On the "S" CH / / u ® (CH ^ SiO OH (CH), (CHjJjC C (CH) 5 ί Susuya alkyl- wherein R-, is subjected to acid hydrolysis at 035 ° C and if appropriate the resulting compound of general formula I, Where
    С C-Su alkyl is hydrolyzed in the presence of pancreatic lipase at room temperature to obtain a compound of general α-formula I, where R is hydrogen, or optionally a compound of general formula I, where R is hydrogen, treated with a diazoalkane to obtain a compound of general formula I where R is SuSualkyl, or with a base at 0-100 ° C to obtain salts, which, if necessary, are treated with acid to obtain a compound of general formula I, where R is hydrogen, after which the target products are isolated.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1031407A3|1983-07-23|Process for preparing derivatives of |-16-phenoxy-9-ketoprostatrienic acid or their acid addition salts
    CA1079725A|1980-06-17|Prostaglandin-acetylene analogues and process for their manufacture
    DK153944B|1988-09-26|ANALOGY PROCEDURE FOR THE PREPARATION OF 9-CHLORO PROSTAGLAND INGREDIENTS
    US3962293A|1976-06-08|13,14-Dihydro-16-fluoro prostaglandin F1
    US4013695A|1977-03-22|4,4,5,5-Tetradehydro-PGE1 analogs
    US4140712A|1979-02-20|20-Hydroxy-prostaglandins
    US4126754A|1978-11-21|11-Deoxy-cis-4,5-didehydro-ω-aryl-PGE compounds
    US3481948A|1969-12-02|2,2 - disubstituted - 3 - acyl - 5alpha - azidothiazolidine-4-carboxylic acids and derivatives
    US4154950A|1979-05-15|15-Epi-15-methyl-16-phenoxy-PGE compounds
    US4294849A|1981-10-13|Prostaglandin analogues
    US3976641A|1976-08-24|Cephalosporin intermediates and process therefor
    SU850000A3|1981-07-23|Method of preparing pyrrolidine derivatives
    SU414793A3|1974-02-05|
    SU976846A3|1982-11-23|Method of producing derivatives of prostacycline or salts thereof
    US4084063A|1978-04-11|8β,12α-PGF2α Compounds
    US3987085A|1976-10-19|8β,11β,12α-PGF2.sub.α compounds
    US3974195A|1976-08-10|2A,2B-Dihomo-15-alkyl-PGF2.sub.α analogs
    US2853497A|1958-09-23|6, 8-bis | 5-hydroxycaprylic acids and delta-lactones thereof
    CA1215362A|1986-12-16|Carbacyclins, process for their preparation thereof,and use thereof as medicinal agents
    US4338316A|1982-07-06|9-Aryloxy prostane derivatives
    US3969396A|1976-07-13|8β, 11β, 12α-PGE2 compounds
    SU525429A3|1976-08-15|The method of obtaining derivatives of 3-oxyiminomethyl cephalosporin or their salts
    US4078021A|1978-03-07|Dimethyl 2-oxo-6-cyanohexyl-phosphonate
    US3966825A|1976-06-29|Process for preparing β-nitroethanethiol
    US4201865A|1980-05-06|Novel prostaglandin analogues
    同族专利:
    公开号 | 公开日
    PL217001A1|1980-03-24|
    NO840256L|1980-01-11|
    GB2025413B|1982-07-28|
    KR890002773B1|1989-07-28|
    FI69061B|1985-08-30|
    FI792149A|1980-01-11|
    PL120633B1|1982-03-31|
    NO152211C|1985-08-21|
    HK41384A|1984-05-18|
    YU44553B|1990-08-31|
    YU44554B|1990-08-31|
    NO152211B|1985-05-13|
    PL121778B1|1982-05-31|
    YU73586A|1986-12-31|
    AU4864179A|1980-02-07|
    HU184185B|1984-07-30|
    NO150836C|1985-01-09|
    DE2927715C2|1987-08-27|
    US4178457A|1979-12-11|
    YU73686A|1986-12-31|
    JPS5513282A|1980-01-30|
    GB2025413A|1980-01-23|
    CA1149802A|1983-07-12|
    IT1121462B|1986-04-02|
    NO152212B|1985-05-13|
    MY8500576A|1985-12-31|
    EP0008003A1|1980-02-20|
    IT7968428D0|1979-07-09|
    CS209927B2|1981-12-31|
    DK157753B|1990-02-12|
    DD146179A5|1981-01-28|
    NO840257L|1980-01-11|
    PL120632B1|1982-03-31|
    YU41870B|1988-02-29|
    DK157753C|1990-07-09|
    PL120604B1|1982-03-31|
    FR2430939A1|1980-02-08|
    NO792283L|1980-01-11|
    EP0008003B1|1983-02-09|
    YU168579A|1983-02-28|
    ZA793293B|1981-02-25|
    NZ190924A|1980-11-28|
    SG82483G|1984-08-03|
    NO150836B|1984-09-17|
    AU527516B2|1983-03-10|
    JPS6210227B2|1987-03-05|
    NO152212C|1985-08-21|
    NO152296B|1985-05-28|
    ES482330A1|1980-08-16|
    NO840258L|1980-01-11|
    DE2964709D1|1983-03-17|
    DK288879A|1980-01-11|
    DE2927715A1|1980-01-24|
    AT2427T|1983-03-15|
    FI69061C|1985-12-10|
    FR2430939B1|1981-08-14|
    NO152296C|1985-09-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    ES449162A1|1975-06-23|1977-12-16|Syntex Inc|16-Phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives|US4328245A|1981-02-13|1982-05-04|SyntexInc.|Carbonate diester solutions of PGE-type compounds|
    US4358603A|1981-04-16|1982-11-09|SyntexInc.|Acetal stabilized prostaglandin compositions|
    US4409239A|1982-01-21|1983-10-11|SyntexInc.|Propylene glycol diester solutions of PGE-type compounds|
    US4804787A|1983-12-22|1989-02-14|SyntexInc.|Processes and intermediates for making 16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives|
    US4912235A|1983-12-22|1990-03-27|SyntexInc.|Processes and intermediates for making 16-phenoxy- and 16-substituted phenoxy-prostatrienoic acid derivatives and their stereoisomers|
    US4600785A|1983-12-22|1986-07-15|SyntexInc.|Processes and intermediates for making 16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives|
    DE3414509C2|1984-04-13|1992-07-02|Schering Ag Berlin Und Bergkamen, 1000 Berlin, De|
    US5057621A|1984-07-31|1991-10-15|SyntexInc.|11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienoic acid derivatives|
    US4618696A|1984-07-31|1986-10-21|SyntexInc.|9-oxo-15α-hydroxy-16-phenoxy and 16-substituted phenoxy 17,18,19,20-tetranorprosta-4,5,13,-trienoates|
    DK346085A|1984-07-31|1986-02-01|Syntex Inc|PROSTATRIIC ACID DERIVATIVES|
    US4792617A|1984-07-31|1988-12-20|SyntexInc.|11-substituted-16-phenoxy and 16-substituted phenoxy-prostatrienioc acid derivatives|
    US4778904A|1985-09-13|1988-10-18|SyntexInc.|Intermediates for making 16-phenoxy- and 16--prostatrienoic acid derivatives|
    KR870009722A|1986-04-11|1987-11-30|원본미기재|Use of Enprostil Type Prostaglandins in Regulating Fat and Carbohydrate Metabolism|
    US4755531A|1986-08-11|1988-07-05|SyntexInc.|Thiol esters of 4,5-allenyl prostaglandins and use thereof as antigastric secretion agents|
    GB8625321D0|1986-10-22|1986-11-26|Glaxo Group Ltd|Chemical compounds|
    US4689419A|1986-11-14|1987-08-25|G. D. Searle & Co.|Novel intermediate compounds in a process for producing 16-phenoxy- and 16-substituted phenoxy-9-keto-prostatrienoic acid derivatives|
    AU742787B2|1997-07-09|2002-01-10|Androsolutions, Inc.|Improved methods and compositions for treating male erectile dysfunction|
    US6103765A|1997-07-09|2000-08-15|Androsolutions, Inc.|Methods for treating male erectile dysfunction|
    US20020037914A1|2000-03-31|2002-03-28|Delong Mitchell Anthony|Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins|
    US20020172693A1|2000-03-31|2002-11-21|Delong Michell Anthony|Compositions and methods for treating hair loss using non-naturally occurring prostaglandins|
    US20020013294A1|2000-03-31|2002-01-31|Delong Mitchell Anthony|Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives|
    US8966971B2|2008-07-28|2015-03-03|Ford Global Technologies, Llc|Vehicle engine with fluid measuring system|
    US8623918B2|2008-10-29|2014-01-07|Novaer Holdings, Inc.|Amino acid salts of prostaglandins|
    US8722739B2|2008-10-29|2014-05-13|Novaer Holdings, Inc.|Amino acid salts of prostaglandins|
    JP2012507552A|2008-10-29|2012-03-29|アエリエ・ファーマシューティカルズ・インコーポレーテッド|Amino acid salt of prostaglandin|
    US20110293549A1|2009-02-03|2011-12-01|Athena Cosmetics, Inc.|Composition, method and kit for enhancing hair|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US05/922,957|US4178457A|1978-07-10|1978-07-10|-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof|
    [返回顶部]